Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing the successful development and manufacture of cell-based products today.
Attendance to our Discussion Groups is available to members of our Cell Member Community. For more information about Membership, please click here.
Taking place Wednesday 7th September 2022 | 15:00 BST
Irina Ramos, Director of BioProcess Technologies & Engineering at AstraZeneca
Taking place Friday 21 October 2022 | 15:00 BST
Taking place Tuesday 29th November 2022 | 15:00 GMT
Reports and write-ups pertaining to previous Discussion Groups are available in our In-Depth section.
Presentation: ‘Current Issues in the Manufacture of hPSC-based Medicines’
Presentation: “Industry Overview and Market Trends- Upstream Bioprocessing” by Amir Reza Goudarzi, Senior Director of Bioprocess Technologies at Bayer
Presentation: “Case Study” by Matthew Coleman, Senior Engineer of Process Engineering Cell Culture, Genentech
Discussion Group Leaders:
Gene therapy development must be fast and efficient. Automation is one of the main priorities affecting the cell and gene industry today to expedite the next-generation development. By following established platforms consisting of common raw materials, parent cell lines, unit operations, and drug substance formulations, automated processes should deliver an intensified procedure for cell therapy development. Challenges remain, however, and in our next cell discussion group we bring together an exclusive panel of key opinion leaders to discuss the key factors behind the market’s growth, priorities, future outlook & challenges.
The question of how best to advance technological strategies for viral vector-based gene therapy is an increasingly prevalent and important one. Our first-ever Cell series discussion group aims to delve into the challenges and opportunities of viral vector manufacturing and delivery. This live session brings together experts to look at the latest developments in the field for an hour of a discussion on design and purification techniques, immunogenicity concerns, and characterisation.
Panel Discussion: Bridging The Gap In the Manufacturing Viral Vectors and Viral Vector Based Gene Therapy
John Moscariello, Executive Director Viral Vector and Gene Editing Process Development, Bristol Myers Squibb
Blair Madison, Senior Director, Genetic Engineering, Poseida Therapeutics
Francesca Vitelli, VP, Cell Therapy and AAV Process Development, Intellia Therapeutics
Kyle Grant, Director of Vector Production, Voyager Therapeutics